Bioprocessing engineer in cleanroom coveralls entering information for manufacturing.

Monoclonal Antibody (mAb) and Recombinant Protein Manufacturing

Innovation for streamlined and accelerated workflows.

  • Bioprocessing scientist transferring liquid into a test tube using a pipette.

    Reimagine bioprocessing to accelerate speed to market.

    Traditional bioprocessing lines can be challenging with outdated technology that can't keep up with new developments in higher-titer cell cultures and increased contaminants. We have a portfolio of solutions that can help your line run more efficiently and with excellent purity and higher yields.


Enabling high-performance single-stage clarification

A line with three curves in it and dots representing steps in a process becoming a line with two curves and dots representing steps in a process.

Save valuable time without sacrificing quality. Take a traditional processing line and condense several steps into one with 3M's portfolio for mAb and recombinant protein clarification and purification.

  • Icon of a three circles with extending lines joining into one line with an arrow on the end.
    Streamlined handling of higher concentration cultures.
  • Icon of clock with circular arrow line around it pointing backwards.
    Increased efficiency through reduced unit operations.
  • Icon of a line with an arrow at the end pointing down.
    Reduced total cost of ownership.

See the 3M difference.

  • Bar chart showing increase of yield by 29%.
    Increased Yield
  • Bar chart showing decrease in cost of 16%.
    Decreased Cost
  • Compare a legacy process with two stages of depth filters in harvesting and traditional AEX and CEX columns in polishing to a process using 3M™ Harvest RC Chromatographic Clarifier and 3M™ Polisher ST. This model shows a 29% increased yield and a 16% decreased cost.
     

    *Commercial Biosolve Process™ software package from Biopharm Services Limited was used for modeling. The results are generated for the hypothetical scenarios. Depending on product and process conditions, the effects shown here may not be realized or may not be realized to the degree shown in the scenarios. 3M data on file.


Next-generation process.

Infographic showing simplified bioprocessing by incorporating 3M™ products.
  • Cover of the brochure.

    Explore applications from 3M portfolio.

    See how 3M solutions can be applied to your process.


  • Cover of the webinar summary.

    Industry trends: Producing mAbs at a commercial scale.

    Biopharmaceutical products (biologics) are transforming the treatment of many diseases like cancer, rheumatoid arthritis (RA), Hepatitis C and Multiple Sclerosis (MS). Monoclonal antibodies (mAbs) and recombinant therapeutic proteins are the two largest biologics segments. Producing these molecules consistently at a commercial scale is both complex and costly.

    Frost & Sullivan has identified key trends driving biopharmaceutical companies to adopt a sandbox approach for development of next-generation biopharmaceutical manufacturing platforms. Read more in the webinar summary.


Want to simplify your process?

Innovation in cell culture production has created additional complexities for the clarification process. 3M offers single-stage and single-use solutions to help simplify your process and increase manufacturing efficiency.

Ask an expert

Fill out this form for any technical or process-related question, and an appropriate 3M Biopharmaceutical representative will contact you to answer your question or direct your request.


Education and Events

  • Scientist in a white 3M lab coat examining a centrifuge.

    Want to learn more about 3M solutions? Read the latest news or connect with us via a learning session or event.


    What’s New


Explore Solutions

All Products

Laptop displaying an online sign up forms for notifications.
Stay up to date on the latest news and product information.
SUBSCRIBE